12 Month Price Forecast For ARYD
Distance to ARYD Price Forecasts
ARYD Price Momentum
๐ค Considering ARYD (ARYD)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 2:13 AM UTC
ARYD Analyst Ratings & Price Targets
ARYD has shown a year-to-date change of 7.7% and a 1-year change of -88.8%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for ARYD. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ARYD Analyst Consensus
ARYD Price Target Range
Latest ARYD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ARYD.
Date | Firm | Analyst | Rating | Change | Price Target |
---|
Stocks Similar to ARYA Sciences Acquisition Corp IV
The following stocks are similar to ARYD based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ARYA Sciences Acquisition Corp IV (ARYD) Financial Data
ARYA Sciences Acquisition Corp IV has a market capitalization of $50.04M with a P/E ratio of 188.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -8.3%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

ARYA Sciences Acquisition Corp IV (ARYD) Company Overview
About ARYA Sciences Acquisition Corp IV
Specializes in acquiring life sciences companies.
The company operates as a blank check company, aiming to merge or acquire businesses in the life sciences and medical technology sectors. It plans to monetize its operations through strategic business combinations with target companies, thereby creating value for its investors.
Incorporated in 2020 and located in New York, Arya Sciences Acquisition Corp IV focuses on North American and European markets, positioning itself in a growing industry with significant potential for returns.
Company Information
Sector
Financial Services
Industry
Shell Companies
Employees
0
CEO
Mr. Adam Leo Stone
Country
United States
IPO Year
2021
Website
www.perceptivelife.com/arya4ARYA Sciences Acquisition Corp IV (ARYD) Latest News & Analysis
Adagio Medical has completed its merger with ARYA Sciences Acquisition Corp IV, a SPAC, enhancing its position in catheter ablation technologies for cardiac arrhythmias.
The completion of Adagio Medical's merger with ARYA IV enhances its market position in cardiac technologies, potentially driving stock performance and attracting investor interest.
The Combined Company anticipates receiving about $42 million from equity and convertible note investors upon closing.
The $42 million funding indicates strong investor confidence, enhances liquidity for growth initiatives, and could positively impact stock performance and valuations.
ARYA Sciences Acquisition Corp IV and Amicus Therapeutics have mutually terminated their Business Combination Agreement due to market conditions, effective immediately.
The termination of the business combination could lead to stock price volatility for ARYA IV and Amicus, impacting investor confidence and future deal-making prospects.
Frequently Asked Questions About ARYD Stock
What is ARYA Sciences Acquisition Corp IV's (ARYD) stock forecast for 2025?
Analyst forecasts for ARYA Sciences Acquisition Corp IV (ARYD) are not currently available. The stock is trading at $1.26.
Is ARYD stock a good investment in 2025?
Analyst ratings for ARYD are not currently available. The stock is currently trading at $1.26. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ARYD stock?
Price predictions from Wall Street analysts for ARYD are not currently available. The stock is trading at $1.26.
What is ARYA Sciences Acquisition Corp IV's business model?
The company operates as a blank check company, aiming to merge or acquire businesses in the life sciences and medical technology sectors. It plans to monetize its operations through strategic business combinations with target companies, thereby creating value for its investors.
What is the highest forecasted price for ARYD ARYA Sciences Acquisition Corp IV?
Price targets from Wall Street analysts for ARYD are not currently available. The stock is trading at $1.26.
What is the lowest forecasted price for ARYD ARYA Sciences Acquisition Corp IV?
Price targets from Wall Street analysts for ARYD are not currently available. The stock is trading at $1.26.
What is the overall ARYD consensus from analysts for ARYA Sciences Acquisition Corp IV?
Analyst ratings for ARYD are not currently available. The stock is trading at $1.26.
How accurate are ARYD stock price projections?
Stock price projections, including those for ARYA Sciences Acquisition Corp IV, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.